Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Thermo"


25 mentions found


81st Street Studio, a Garden of Artful Delight
  + stars: | 2023-09-07 | by ( Laurel Graeber | ) www.nytimes.com   time to read: +1 min
But maybe most intriguing are two round screens, each featuring a blinking, animated eye. When a child approaches a screen, the eye shuts, and images from the Met’s collection take its place. The other eye screen, at toddler level, reveals images from modern video art. By turning dials, visitors can change variables like shadow, color, angle and distance and see how they affect the objects pictured. Art and science intersect again in the music station, whose instruments might seem more appropriate for Dr. Seuss than for a symphony.
Persons: , Nina Callaway, we’re, ” Holder, Seuss, Kip Washio Organizations: Yamaha
In prepared remarks for a speech, she said the Fed is "well positioned to proceed cautiously in this uncertain economic environment." Those sentiments mesh with recent statements from Fed Chairman Jerome Powell and Fed Gov. I did not hear a resounding endorsement of the 27.5% tariffs on Chinese EVs. If you like this story, sign up for Jim Cramer's Top 10 Morning Thoughts on the Market email newsletter for free. Thermo Fisher ScientificUBS downgrades "sainted" Block ToastMorgan Stanley goes equal weight from underweight (hold from sell) on First SolarAeroVironmentSouthwest Airlines
Persons: Susan Collins, Jerome Powell, Christopher Waller, Gina Raimondo, Jim Cramer's, Leerink, Morgan Stanley Organizations: Boston Federal, Fed, Oracle, Microsoft, Fisher Scientific UBS
Many view healthcare as a defensive sector because it has constant demand and is somewhat insulated from the economy. In the latest week, investors pulled a net $1.4 billion from the sector, the biggest weekly outflow since May 2022. Overall, the healthcare sector - which ranges from health insurers like UnitedHealth to pharmaceutical companies like Pfizer to small biotechs - has received the third largest inflows of any sector year to date, BofA's data showed. This would weaken the case for loading up on healthcare stocks. Overall, healthcare sector earnings are expected to lag this year as COVID-related revenues decline 13% versus a 1.8% rise for the overall S&P 500.
Persons: Brendan McDermid, Bob Kalman, Emily Roland, Dan Lyons, Janus Henderson, you've, Lyons, Kalman, Joe Biden's, Margie Patel, Patel, David Randall, Ira Iosebashvili, Megan Davies, David Gregorio, Richard Chang Organizations: New York Stock Exchange, REUTERS, Atlanta Federal, BofA Global Research, Pfizer, Miramar Capital, Healthcare, John Hancock Investment Management, Janus Henderson Investors, U.S, Bristol Myers Squibb, Allspring Global Investments, Thomson Locations: New York City, U.S
[1/3] A general view of the drug product manufacturing laboratory in biologics and sterile injectables, Catalent, in Brussels, Belgium June 27, 2023. REUTERS/Yves Herman/File Photo Acquire Licensing RightsAug 25 (Reuters) - Novo Nordisk Chief Executive Lars Fruergaard Jorgensen said on Friday he was confident Catalent (CTLT.N) would resolves its problems making Novo's hugely-popular weight-loss drug Wegovy as the company scrambles to boost output to meet soaring demand. "I am confident in that," Jorgensen said at a Reuters Newsmaker event, when asked about the issues Catalent has had. Novo hopes to have a third external facility filling and finishing the injection pens by 2024, Jorgensen said. Even so, it will be "quite some years" before the company can satisfy the whole market for Wegovy, Jorgensen said.
Persons: Yves Herman, Lars Fruergaard Jorgensen, Jorgensen, Catalent, Novo, Maggie Fick, Josephine Mason, Mark Potter Organizations: REUTERS, Novo Nordisk, Reuters, Wegovy, Thomson Locations: Brussels, Belgium, Danish
A selection of injector pens for the Wegovy weight loss drug are shown in this photo illustration in Chicago, Illinois, U.S., March 31, 2023. REUTERS/Jim Vondruska/Illustration/File Photo Acquire Licensing RightsLONDON, Aug 23 (Reuters) - Novo Nordisk (NOVOb.CO) has hired Thermo Fisher (TMO.N) as its second contract manufacturer for its hugely popular weight-loss drug Wegovy, a source familiar with the matter told Reuters. Thermo is doing the filling of the Wegovy injection pens at its factory in Greenville, North Carolina, the source said, declining to be named because the information is confidential. Novo Chief Financial Officer Karsten Munk Knudsen told Reuters in May the company had signed up a second contract manufacturer in the United States, but the identity of the company has not previously been reported. Wegovy launched in the United States in June 2021, the first-to-market in a new class of highly effective weight-loss drugs.
Persons: Jim Vondruska, Karsten Munk Knudsen, Wegovy, Knudsen, Catalent's, Maggie Fick, Josephine Mason, Mark Potter Organizations: REUTERS, Novo Nordisk, Reuters, Novo, Thomson Locations: Chicago , Illinois, U.S, Greenville , North Carolina, United States, Danish, Brussels, Belgium
A selection of injector pens for the Wegovy weight loss drug are shown in this photo illustration in Chicago, Illinois, U.S., March 31, 2023. REUTERS/Jim Vondruska/Illustration/File Photo Acquire Licensing RightsLONDON, Aug 23 (Reuters) - Novo Nordisk (NOVOb.CO) has hired Thermo Fisher (TMO.N) as its second contract manufacturer for its hugely popular weight-loss drug Wegovy, a source familiar with the matter told Reuters. Thermo is doing the filling of the Wegovy injection pens at its factory in Greenville, North Carolina, the source said, declining to be named because the information is confidential. Novo Chief Financial Officer Karsten Munk Knudsen told Reuters in May the company had signed up a second contract manufacturer in the United States, but the identity of the company has not previously been reported. Wegovy launched in the United States in June 2021, the first-to-market in a new class of highly effective weight-loss drugs.
Persons: Jim Vondruska, Karsten Munk Knudsen, Wegovy, Knudsen, Catalent's, Maggie Fick, Josephine Mason, Mark Potter Organizations: REUTERS, Novo Nordisk, Reuters, Novo, Thomson Locations: Chicago , Illinois, U.S, Greenville , North Carolina, United States, Danish, Brussels, Belgium
Ethiopian Airlines to manufacture parts in venture with Boeing
  + stars: | 2023-08-18 | by ( ) www.reuters.com   time to read: +1 min
An Ethiopia’s Airlines Boeing 737 Max 8 plane to take off on a demonstration trip to resume flights from the Bole International Airport in Addis Ababa, Ethiopia February 1, 2022. REUTERS/Tiksa Negeri Acquire Licensing RightsNAIROBI, Aug 18 (Reuters) - Ethiopian Airlines will start manufacturing aircraft parts in a venture with Boeing (BA.N) at an initial cost of $15 million, the government's investment agency said on Friday. The state-owned carrier, which is the biggest in Africa, has already signed the deal that also involves the local state Industrial Parks Development Corporation, the Ethiopian Investment Commission said on X, formerly known as Twitter. The venture will make "aerospace parts, including aircraft thermo-acoustic insulation blankets, electrical wire harnesses, and other parts," the commission said. It was not immediately clear if Ethiopian Airlines has also suffered from similar lack of parts.
Persons: George Obulutsa, Duncan Miriri, Angus MacSwan Organizations: Ethiopia’s Airlines Boeing, Max, REUTERS, Tiksa, Acquire, Rights, Ethiopian Airlines, Boeing, Industrial Parks Development Corporation, Ethiopian Investment Commission, Twitter, Kenya Airways, Thomson Locations: Bole, Addis Ababa, Ethiopia, Rights NAIROBI, Africa, Ukraine
On Thursday's "Ask Halftime," traders answered questions from CNBC Pro subscribers about which stocks to buy, hold or sell right now. Jenny Harrington of Gilman Hill Asset Management discussed why she sees Thermo Fisher Scientific as a stock worth holding for the long term. Capital Wealth Planning's Kevin Simpson shared his thesis on investing in Lockheed Martin and why now is a good entry point to buy shares.
Persons: Jenny Harrington, Kevin Simpson, Lockheed Martin Organizations: CNBC Pro, Management, Lockheed
China's slowing economy is chipping away at some American companies' revenues. China's July economic report didn't mention youth-unemployment statistics after it soared to 21.3% in the second quarter, citing economic and social changes. While Chinese manufacturing and construction are struggling to recover, some American companies with strong ties to China are also feeling the effects. Dow's rival DuPont also reported a drop in China sales from existing operations, a 14% year-over-year fall. To be sure, some American companies have performed well in China over the past few months.
Persons: Gamble, Stephen Williamson, Danaher, Rainer Blair, Howard Ungerleider, Edward Breen, Marriott Organizations: DuPont, Danaher, Procter, Service, Citigroup, Intel, Toyota, Nissan, Apple, Starbucks, Street Journal, Monetary Fund Locations: China, Wall, Silicon, American, Ohio, Greater China, Beijing
Aug 9 (Reuters) - Charles River Laboratories International (CRL.N) beat Wall Street estimates for second-quarter results on Wednesday, as the strong demand for contract researcher's tools and services cushioned the impact of suspended non-human primates' (NHP) shipment. The statement comes after Charles River in February suspended the shipment of NHPs from Cambodia as the Department of Justice and U.S. Fish and Wildlife Service investigated the company over smuggling of wild long-tailed macaques to the United States. The Massachusetts-based company tightened its full-year profit forecast to the range of $10.30 to $10.90 per share, compared with $9.90 to $10.90 previously expected. Excluding items, the company earned $2.69 per share in the quarter ended July 1, beating analysts' average estimate of $2.64 per share.
Persons: Charles River, Charles River's, Vaibhav Sadhamta, Shweta Agarwal Organizations: River Laboratories, Department of Justice, Fish, Wildlife Service, Thomson Locations: United States, NHPs, Cambodia, The Massachusetts
To an ordinary person, the answer is obviously yes. Lacks, a Black mother of five, was dying of cervical cancer in 1951 when doctors at Johns Hopkins Hospital in Baltimore biopsied tissues from her cervix. Whatever the case, cells from the research sample were later found to be highly valuable because they were the first that could divide indefinitely in a laboratory. And cells are “de-identified,” unlike Lacks’s cells, which are named HeLa to this day. What’s still debated is whether people have a legitimate ownership claim in the first place.
Persons: it’s, Henrietta Lacks, HeLa, What’s Organizations: Johns Hopkins Hospital Locations: Baltimore
A handful of the most well-known technology stocks are being somewhat ignored by socially conscious funds, according to Bernstein. Big technology names including Apple , Amazon , Meta , Microsoft and Alphabet were among the most underweighted stocks by North American funds that consider environmental, social and corporate governance factors when screening investment ideas. Big Tech has roared back to life this year, coming off 2022's selloff as investors bet on a better interest rate environment. Here are the 10 most underweighted stocks by North American funds: On the flip side, a wide swath of stocks accounted for the most held, relatively. Barclays analyst Craig Rye said the stock could actually benefit if hurricane season is worse than was previously expected.
Persons: Bernstein, Danaher, Craig Rye, Rye, , Michael Bloom Organizations: Apple, Meta, Microsoft, North, Big Tech, Software, Nvidia, Insurance, Barclays, Fisher, Deere
This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. https://www.wsj.com/articles/henrietta-lacks-family-hela-cells-thermo-fisher-settlement-d93e60e5
Persons: Dow Jones
Henrietta Lacks changed modern medicine when doctors took her cells without her consent in 1951. Despite that incalculable impact, the Lacks family had never been compensated. Henrietta Lacks' cells have been part of many medical breakthroughs. "The exploitation of Henrietta Lacks represents the unfortunately common struggle experienced by Black people throughout history," the complaint reads. "It was a long fight — over 70 years — and Henrietta Lacks gets her day."
Persons: Henrietta, HeLa, Ben Crump, Crump, didn't, Rebecca Skloot, Oprah Winfrey, Johns Hopkins, Fisher, George Floyd's, Alfred, Carter Jr, Chris Van Hollen, Ben Cardin, Van Hollen Organizations: Service, Johns Hopkins Hospital, Fisher Scientific Inc, Associated Press, HBO, Johns Hopkins Medicine, Maryland Democrats Locations: Wall, Silicon, Waltham , Massachusetts, Baltimore, Virginia, United States, Baltimore's
The family of Henrietta Lacks, the Black woman whose cancer cells were taken without consent and used to pioneer numerous medical discoveries, reached a settlement on Monday with a biotechnology company that had used the cells. Lacks, who died decades ago, accused the company, Thermo Fisher Scientific, of selling the cells and trying to secure intellectual property rights on the products the cells were used to help develop without compensating the family or seeking their permission or approval. The terms of the settlement are confidential, lawyers for both parties said in a statement. Thermo Fisher, a Massachusetts-based biotechnology company, and the legal team for Ms. Lacks’s family released identical statements announcing the settlement. “The parties are pleased that they were able to find a way to resolve this matter outside of Court and will have no further comment,” the statements said.
Persons: Henrietta Lacks, Lacks’s Locations: Massachusetts
A health-care fund with a strong track record could be in a sweet spot for investors who are looking to take some risk off the table, according to Bank of America. "Since 2006, HCES has been a 'goldilocks' trade for investors looking for high-beta healthcare exposure without extreme volatility," the note said. The firm's top-rated ETF in the space is the iShares U.S. Medical Devices ETF (IHI) , which helps investors avoid the volatile biotech stocks found in broader health-care sector funds. IHI 5Y mountain The IHI has averaged a total return of more than 10% over the past five years. In our view, the trade is far less crowded than broad healthcare for investors looking for defensive exposure," Woodard said.
Persons: Jared Woodard, HCES, Woodard, — CNBC's Michael Bloom Organizations: Bank of America . Investment, Medical Devices, Fisher, Abbott Laboratories, Bank of America Locations: U.S
SummaryCompanies Alphabet climbs on Q2 profit beatMicrosoft slides as AI spending grows faster than revenueFed's rate decision awaited at 2:00 p.m. Meta Platforms <META.O> rose 1.8% after Alibaba's cloud unit said it would support the Facebook owner's open-source AI model Llama. The Fed is expected to deliver a 25-basis point interest rate hike later in the day, though there is less clarity over what the central bank will do at subsequent meetings. ET, Dow e-minis were down 65 points, or 0.18%, S&P 500 e-minis were down 7.25 points, or 0.16%, and Nasdaq 100 e-minis were down 43.75 points, or 0.28%. Wells Fargo (WFC.N) climbed 2.8% after the bank's board authorized a new share buyback program of up to $30 billion.
Persons: Joshua Warner, Stefan Koopman, Wells Fargo, Bansari Mayur Kamdar, Johann M, Savio D'Souza, Anil D'Silva Organizations: Microsoft, Dow, Nasdaq, Wall, Google, NYSE, Facebook, Rabobank, Dow e, Federal Trade Commission, Thomson Locations: Bengaluru
Morning Bid: Markets brace for Fed decision, earnings flood
  + stars: | 2023-07-26 | by ( ) www.reuters.com   time to read: +2 min
Investors will be listening carefully to Chair Jerome Powell for indications of whether or not another interest rate hike is in the pipeline. The Fed's communication could set the tone for markets ahead of policy decisions from the European Central Bank (ECB) on Thursday and the Bank of Japan (BOJ) on Friday. Reuters GraphicsEuro zone June M3 annual growth and lending data on Wednesday are unlikely to affect markets ahead of the ECB's decision. Chinese stock markets were mostly lower on Wednesday following a steep rally the day before. China's blue-chip CSI300 (.CSI300) index was down 0.3% while the CSI 300 Real Estate index gained 0.2%.
Persons: Brigid Riley, Jerome Powell, HSI, Sonali Desai, Edmund Klamann Organizations: Federal Reserve, Federal, Market, European Central Bank, Bank of Japan, ECB, Reuters, Fisher, Union Pacific Corp, eBay, Boeing, Microsoft, Carrefour, Danone, GSK, CSI, CPI, Reserve Bank of Australia, U.S, Fed, Thomson Locations: United States, U.S, Europe, France, Asia, China
Alphabet — The Google parent popped more than 6% after topping Wall Street's second-quarter earnings expectations, fueled by growth in its cloud-computing segment. Microsoft, however, did beat Wall Street's estimates, reporting earnings of $2.69 per share on $56.19 billion in revenue. Snap topped second-quarter expectations, reporting a narrower-than-expected loss of 2 cent a share on $1.07 billion in revenue. Wells Fargo also said that its board approved a previously announced dividend hike to 35 cents from 30 cents per share. The company topped earnings but fell short on revenue expectations, reporting adjusted earnings per share of 63 cents on $29.92 billion in revenue.
Persons: Ruth Porat, Refinitiv, Wells Fargo, popper, , Sarah Min, Yun Li, Hakyung Kim, Jesse Pound Organizations: Google, Microsoft, Boeing, Texas, — Texas, Teladoc Health, Dish, Bloomberg News, Fisher, Pacific Locations: Mountain View , California, Banc, California
Final Trades: Broadcom, Conocophillips, Thermo Fisher
  + stars: | 2023-07-12 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailFinal Trades: Broadcom, Conocophillips, Thermo FisherThe "Halftime Report" traders give their top picks to watch for the second half.
Organizations: Broadcom, Conocophillips
Thermo Fisher to acquire CorEvitas for about $913 million
  + stars: | 2023-07-06 | by ( ) www.reuters.com   time to read: +2 min
Thermo Fisher has been on an acquisition spree in recent years as it strives to become a one-stop shop for biopharma services. CorEvitas is expected to boost Thermo Fisher's annual adjusted earnings per share by 3 cents next year. The data provider also has the potential to generate $110 million of revenue in 2023, Thermo Fisher said. CorEvitas' data intelligence platform would be added to Thermo Fisher's laboratory products and biopharma services unit, upon completion of the deal. Shares of Massachusetts-based Thermo Fisher were down 1.3% at $514 in early trading.
Persons: Fisher, CorEvitas, Puneet, Sriparna Roy, Shilpi Majumdar Organizations: SVB Securities, Audax Private Equity, Massachusetts, Thomson Locations: U.S, Boston, Bengaluru
To what extent the test will improve outcomes and save lives is not clear, however, as there is no effective treatment for pre-eclampsia, which usually eases after birth. “We don’t have a therapy that reverses or cures pre-eclampsia other than delivery of the baby, which is more like a last resort,” Dr. Woelkers said. The new blood test, made by Thermo Fisher Scientific, has been available in Europe for several years. It is intended for pregnant women who are hospitalized for a blood pressure disorder in the 23rd to 35th weeks of gestation. “A lot of women will have edema and headaches.” (Edema means swelling.)
Persons: , Woelkers, , Sarosh Rana Organizations: Fisher, University of Chicago Locations: Europe
Top 10 things to watch in the stock market Tuesday
  + stars: | 2023-06-20 | by ( Jeff Marks | ) www.cnbc.com   time to read: +3 min
It's a new week but the recent stock market rally makes for a not-so-great set up as Jim Cramer told the Investing Club Monday evening in his weekly column. Jim and "Mad Money" are in Detroit for all things Ford (F) with CEO Jim Farley, covering everything from Ford Blue to Ford Pro to Ford Model e (electric vehicles). Bank of America adds Club stock Amazon (AMZN) to its US 1 list. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.
Persons: Jim Cramer, Dow, Jim, Jim Farley, They'll, Elon Musk, Sartorius, Cowen, Eli Lilly, Raymond James, Morgan Stanley, Philip Morris, Jim Cramer's Organizations: Nasdaq, Ford, Ford Pro, Ford Model, Elon, Bank of America, Nvidia, Club, Dice Therapeutics, Avis Budget, Citi, Delta Air Lines, DAL, PayPal, Nike, Dow, Barclays, Jim Cramer's Charitable, CNBC Locations: Detroit
A warning from UnitedHealth Group executives Wednesday that demand for medical services was rising sent insurance stocks tumbling and, in turn, hit investors who bet on health care. The biggest health-care exchange-traded fund, the $41 billion Health Care Select Sector SPDR Fund (XLV) , lost 1% Wednesday. The $17 billion Vanguard Health Care ETF (VHT) also fell about 1%. XLV 5D mountain The XLV was dragged down by insurance stocks on Wednesday. Some Wall Street analysts said the dramatic sell-off in typically stodgy insurance stocks could prove to be a buying opportunity.
Persons: John Franklin Rex, Rex, that's, Cantor Fitzgerald, Sarah James, — CNBC's Michael Bloom Organizations: UnitedHealth Group, Humana, CVS Health, Health Care, CVS, Devices, Abbott Laboratories
Morgan Stanley named a slew of must-own stocks this week that the firm said are firing on all cylinders ahead of summer. They include Bath & Body Works , Take-Two Interactive, RBC Bearings, Thermo Fisher Scientific and American Express. RBC Bearings "[The] growth story remains intact," analyst Kristine Liwag said of the aerospace and industrial bearings maker. "We continue to view RBC Bearings as a high-quality industrials compounder with attractive growth and margin expansion potential," she wrote. … We continue to view RBC Bearings as a high-quality industrials compounder with attractive growth and margin expansion potential.
Persons: Morgan Stanley, Morgan, Matthew Cost, he's, Kristine Liwag, Liwag, Alex Straton, BBW, Straton, mgmt, Amex hasn't Organizations: CNBC, Body, Interactive, RBC, Fisher Scientific, American Express, Dodge Industrial, Locations: Biopharma
Total: 25